
-
Galapagos NV NasdaqGS:GLPG Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Location: Generaal De Wittelaan L11 A3, Mechelen, 2800, Belgium | Website: https://www.glpg.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-1.371B
Cash
3.297B
Avg Qtr Burn
-59.05M
Short % of Float
6.56%
Insider Ownership
0.00%
Institutional Own.
47.61%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Jyseleca (Filgotinib) Details Ulcerative colitis | Approved Quarterly sales | |
GLPG3667 Details Dermatomyositis | Phase 3 Data readout | |
Filgotinib Details Axial spondyloarthritis | Phase 3 Data readout | |
Filgotinib Details Crohns disease | Phase 3 Update | |
GLPG3667 Details Systemic lupus erythematosus | Phase 2 Data readout | |
GLPG5301 BCMA CAR-T Details Multiple myeloma, High Refractory Multiple Myeloma | Phase 1/2 Data readout | |
GLPG5101 (CD19 CAR-T) Details Non-Hodgkin lymphoma, Cancer | Phase 1/2 Data readout | |
GLPG5201 (CD19 CAR-T) Details Small lymphocytic lymphoma , Chronic lymphocytic leukemia | Phase 1/2 Update | |
GLPG5101 (CD19 CAR-T) Details Systemic lupus erythematosus, Autoimmune disease | Failed Discontinued | |
Ziritaxestat (GLPG1690) Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
GLPG3970 (SIK2/3 inhibitor) Details Psoriasis, Rheumatoid arthritis, Ulcerative colitis, Systemic lupus erythematosus | Failed Discontinued | |
GLPG4716 (CHIT1/AMCase inhibitor) Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
GLPG2737 (CFTR inhibitor) Details Autosomal Dominant Polycystic Kidney Disease | Failed Discontinued | |
GLPG1205 (GPR84 inhibitor) Details Idiopathic pulmonary fibrosis | Failed Discontinued |